Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced April 6, 2026
Introduced
Passed House
Passed Senate
To President
Became Law
Latest: October 14, 2026: Message on Senate action sent to the House.
Summary
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.